Digestive and Liver Disease · 2024 · 12 citations · 20 references
MedicineInternal MedicineClinical EpidemiologyGastroenterologyNutritional EpidemiologyChronic Liver DiseaseHepatic ImpairmentInflammatory Bowel DiseaseLiver DiseaseMetabolic Liver DiseaseMetabolic SyndromeAlcoholic Liver Disease SteatosisCardiometabolic DiseaseLiver Disease ComplicationsLiver Disease PrognosisLiver Disease Risk AssessmentLong-term Cardiometabolic RiskPrimary Outcome AnalysisProspective Cohort Data
Purpose To examine the mortality risk associated with metabolic dysfunction-associated steatotic liver disease (MASLD), MASLD type, lean/non-lean MASLD and different cardiometabolic risk factors (CMRFs) in patients with inflammatory bowel disease (IBD) based on a long-term prospective cohort. Methods Prevalent IBD patients at baseline who were free of alcoholic liver disease, cancer and hepatitis B/C virus seropositive were included (N=4622). MASLD, MASLD type [pure MASLD, MASLD with increased alcohol intake (MetALD)], lean/non-lean MASLD and CMRFs at baseline were defined according to the latest criteria proposed by AASLD and EASL. Primary outcome was all-cause mortality. Cox proportional hazard model was used to examine the association. Results Overall, 1,763 (38.1%) were diagnosed with MASLD. During a median of 13.3-year follow-up, 451 all-cause deaths were identified. Compared with IBD-only patients, those with MASLD had a 58% excess risk of mortality (HR=1.58, 95%CI:1.07–2.32). Furthermore, as number of CMRFs increased in MASLD patients, mortality risk was significantly increased (P trend =0.005), with a 85% and 83% higher risk in MASLD with 3 CMRFs (HR=1.85, 95%CI:1.20–2.85) and ≥4 CMRFs (HR=1.83, 95%CI:1.16–2.89) versus IBD-only patients. Specifically, similar elevated mortality risk was observed in either pure MASLD (HR= 1.62, 95%CI:1.09–2.43) or MetALD (HR=2.03, 95%CI:1.24–3.32). Moreover, the excess mortality risk was both indicated in lean (HR=3.14, 95%CI:1.57–6.29) and non-lean MASLD (HR=1.67, 95%CI:1.12–2.48). Conclusions MASLD, either pure MASLD or MetALD, as well as lean/non-lean MASLD, is associated with increased mortality risk in IBD patients, with greater risk as number of cardiometabolic risk factors increased and evidently higher risk in lean MASLD patients.
20
Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease
Jeong‐Hoon Lee, Donghee Kim, Hwa Jung Kim et al. · Digestive and Liver Disease · 2009 · 1.6K citations
Medicine, Pathology, Hepatology +11
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation
Fei Chen, Saeed Esmaili, Geraint B. Rogers et al. · Hepatology · 2019 · 322 citations · Full text